Please assess the completion status of the following clinical trial:

Trial Title: Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~In order to participate in the study, subjects must~* Be at least 18 years of age and no older than 55 years of age.~* Weigh more than 100 pounds.~* Have a DSM-IV diagnosis of cocaine dependence.~* Be seeking treatment for cocaine dependence.~* Have a urine sample positive for qualitative cocaine toxicology at initial screening.~* Have the ability to understand, and having understood, provide written informed consent to comply with the treatment protocol.~* Have a history and brief physical examination that demonstrate no clinically significant contraindication for participating in the study, in the judgment of the admitting physician and the Principal Investigator.~* Have normal, or, if necessary, corrected visual acuity, visual fields, and normal fundoscopy findings~Exclusion Criteria:~* In order to participate in the study, subjects must not:~  * Meet DSM-IV criteria for current dependence on any psychoactive substance other than cocaine, alcohol, nicotine, or marijuana or physiological dependence on alcohol requiring medical detoxification.~ * Have neurological or psychiatric disorders such as: psychosis, bipolar illness, major depression, organic brain disease, dementia, any disorder which would require ongoing treatment or which would make study agent compliance difficult, history of suicide attempts assessed and/or current suicidal ideation/plan.~ * Have serious medical illnesses or other potentially life threatening or progressive medical illness other than addiction that may compromise subject safety or study conduct.~ * Have a history of traumatic head injury.~ * Be mandated by a court to obtain treatment for cocaine dependence.~ * Have been treated for cocaine addiction, or abstained from cocaine use for a significant period, within the 6 months preceding screening.~ * Be unable to complete the study protocol because of probable incarceration or relocation from the clinical area.~ * Have AIDS (although AIDS is an exclusion criterion, a positive antibody titer to HIV is not).~ * Have active syphilis that has not been treated or refuse treatment for syphilis~ * Have a history of neuroleptic malignant syndrome.~ * Have known or suspected hypersensitivity to vigabatrin or any other GABAergic drug.~ * Have received a drug with known potential for toxicity to a major organ system within 30 days prior to study entry (e.g., isoniazid, methotrexate).~ * Have participated in any experimental study within 4 weeks, or participated in any clinical trial utilizing vigabatrin.~ * Be pregnant or lactating.~ * Have any clinically significant abnormal laboratory value.~ * Have had electroconvulsive therapy with the 3 months preceding screening.~ * Have had any opiate-substitutes (methadone, LAAM, buprenorphine) within 2 months preceding screening.~ * Have a history of i.v. cocaine (or other psychoactive drug) use within 2 months preceding screening.~ * Have a current or past history of seizure disorder, including alcohol- or stimulant related seizure, febrile seizure, or significant family history of idiopathic seizure disorder.~ * Have a visual field defect, or factor predisposing to visual field defects, including glaucoma, severe myopia, retinal disorder, cataracts, diabetes or uncontrolled hypertension.~ * Have my illness, condition, and use of medications, in the opinion of the Principal Investigator and the admitting physician, which would preclude safe or successful completion of the study.~ * Be using vigabatrin or any medication that could interact adversely with vigabatrin administration, based on the longest time interval of A or B below:~    * A) Five half-lives of other medication or active metabolite(s), whichever is longer;~   * B) Two weeks.~ * Be lactose intolerant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Subjects will receive vigabatrin in escalating doses to 3 grams per day over three weeks, continued for 4 weeks and then tapered to zero over the next 2 weeks.
- B (Type: PLACEBO_COMPARATOR): Orange juice and administration identical to Arm A.

Based on this trial design, predict the completion outcome and termination type (if applicable).